These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32166174)

  • 1. Catecholamines: Knowledge and understanding in the 1960s, now, and in the future.
    Stanford SC; Heal DJ
    Brain Neurosci Adv; 2019; 3():2398212818810682. PubMed ID: 32166174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nature of catecholamine-containing neurons in the enteric nervous system in relationship with organogenesis, normal human anatomy and neurodegeneration.
    Natale G; Ryskalin L; Busceti CL; Biagioni F; Fornai F
    Arch Ital Biol; 2017 Sep; 155(3):118-130. PubMed ID: 29220864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catecholamines and attention. I: Animal and clinical studies.
    Clark CR; Geffen GM; Geffen LB
    Neurosci Biobehav Rev; 1987; 11(4):341-52. PubMed ID: 3325864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.
    Dell'Osso B; Palazzo MC; Oldani L; Altamura AC
    CNS Neurosci Ther; 2011 Dec; 17(6):723-32. PubMed ID: 21155988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine and the regulation of cognition and attention.
    Nieoullon A
    Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.
    Haapalinna A; Leino T; Heinonen E
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):342-51. PubMed ID: 14566451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine: the rewarding years.
    Marsden CA
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S136-44. PubMed ID: 16402097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
    Heal DJ; Pierce DM
    CNS Drugs; 2006; 20(9):713-38. PubMed ID: 16953648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Structural and functional organization of the cerebral dopaminergic system].
    Barishpolets VV; Fedotova IuO; Sapronov NS
    Eksp Klin Farmakol; 2009; 72(3):44-9. PubMed ID: 19642593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C; Schatzberg AF
    Psychopharmacol Bull; 2024 Jul; 54(3):8-59. PubMed ID: 38993656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia.
    Gupta AK; Pokhriyal R; Das U; Khan MI; Ratna Kumar D; Gupta R; Chadda RK; Ramachandran R; Goyal V; Tripathi M; Hariprasad G
    Neuropsychiatr Dis Treat; 2019; 15():2073-2085. PubMed ID: 31410011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between simvastatin and metoprolol with respect to cardiac beta-adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients.
    Nette AF; Abraham G; Ungemach FR; Oertel R; Kirch W; Leineweber K; Mohr FW; Dhein S
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Aug; 372(2):115-24. PubMed ID: 16215713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 Oct; 154(2):353-63. PubMed ID: 15313023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction.
    Arnsten AF
    CNS Drugs; 2009; 23 Suppl 1():33-41. PubMed ID: 19621976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice.
    Moura E; Afonso J; Hein L; Vieira-Coelho MA
    Br J Pharmacol; 2006 Dec; 149(8):1049-58. PubMed ID: 17075569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.